Canagliflozin is a potential cardioprotective drug but exerts no significant effects on pirarubicin‑induced cardiotoxicity in rats

  • Authors:
    • Hongwei Shi
    • Qingfu Zeng
    • Yunjie Wei
    • Hong Yang
    • Heng Tang
    • Dan Wang
    • Peng Pu
    • Rui Feng
  • View Affiliations

  • Published online on: August 5, 2021     https://doi.org/10.3892/mmr.2021.12342
  • Article Number: 703
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pirarubicin (THP), one of the anthracycline anticancer drugs, is widely used in the treatment of various types of cancer, but its cardiotoxicity cannot be ignored. Canagliflozin, the first sodium‑glucose co‑transporter‑2 inhibitor approved by the USA FDA, has been shown to have a significant effect on cardiovascular damage caused by diabetes. However, it has not been reported whether it can resist THP‑induced cardiotoxicity. The aim of the present study was to investigate the effect of canagliflozin on THP‑induced cardiotoxicity and its mechanism. A rat model of cardiotoxicity induced by THP was established and canagliflozin treatment was performed at the same time. The changes of electrocardiography, cardiac coefficient and echocardiogram were observed. The levels of lactate dehydrogenase, brain natriuretic peptide, creatine kinase MB, cardiac troponin T, superoxide dismutase (SOD) and malondialdehyde were detected. The expression of SOD2, NADPH oxidase 2, pro/cleaved‑caspase‑ and Bcl‑2/Bax were evaluated by western blotting. The primary culture of cardiomyocytes was prepared to explore the effect in vitro. After eight weeks, a series of cardiotoxicity manifestations were observed in THP rats. However, canagliflozin treatment had no significant effect on the above adverse reactions. Similarly, further studies showed that canagliflozin had no significant effect on THP‑induced cardiomyocyte injury in vitro. The present study showed that there was no significant protective effect of canagliflozin on THP‑induced cardiotoxicity and cardiomyocyte injury.
View Figures
View References

Related Articles

Journal Cover

October-2021
Volume 24 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shi H, Zeng Q, Wei Y, Yang H, Tang H, Wang D, Pu P and Feng R: Canagliflozin is a potential cardioprotective drug but exerts no significant effects on pirarubicin‑induced cardiotoxicity in rats. Mol Med Rep 24: 703, 2021.
APA
Shi, H., Zeng, Q., Wei, Y., Yang, H., Tang, H., Wang, D. ... Feng, R. (2021). Canagliflozin is a potential cardioprotective drug but exerts no significant effects on pirarubicin‑induced cardiotoxicity in rats. Molecular Medicine Reports, 24, 703. https://doi.org/10.3892/mmr.2021.12342
MLA
Shi, H., Zeng, Q., Wei, Y., Yang, H., Tang, H., Wang, D., Pu, P., Feng, R."Canagliflozin is a potential cardioprotective drug but exerts no significant effects on pirarubicin‑induced cardiotoxicity in rats". Molecular Medicine Reports 24.4 (2021): 703.
Chicago
Shi, H., Zeng, Q., Wei, Y., Yang, H., Tang, H., Wang, D., Pu, P., Feng, R."Canagliflozin is a potential cardioprotective drug but exerts no significant effects on pirarubicin‑induced cardiotoxicity in rats". Molecular Medicine Reports 24, no. 4 (2021): 703. https://doi.org/10.3892/mmr.2021.12342